According to a new report, published by KBV research, The Global Motion Sickness Treatment Market size is expected to reach $481 Million by 2029, rising at a market growth of 3.2% CAGR during the forecast period.
The Anticholinergics market is estimated to grow at a CAGR of 3.6% during (2023 - 2029). This is due to the fact that anticholinergics are drugs that block the neurotransmitter acetylcholine in the central and peripheral nervous systems. The growth in anticholinergic drugs is due to their advantages and effectiveness in preventing motion sickness. Although various treatments are available for motion sickness, including over-the-counter medications and prescription drugs, anticholinergics, particularly scopolamine transdermal patches, are highly efficacious.
The Oral market is leading the Global Motion Sickness Treatment Market by Route of Administration in 2022; thereby, achieving a market value of $344.4 Million by 2029. The growth is attributed to the diverse range of products offered in this segment by the major players. The high demand for antihistaminic medications is primarily met through tablet, capsule, and pill dosage forms. Also, prominent industry leaders are providing a diverse selection of oral medications for motion sickness that offer a more economical alternative to other treatment options, contributing to the segment's growth.
The Online Pharmacies market is anticipated to grow at a CAGR of 4.2% during (2023 - 2029). This is due to the quick accessibility, time-saving benefits, and significant discounts and incentives offered by online providers. Additionally, there has been a significant increase in online services, and the realm of electronic commerce is becoming dominant. Online pharmacies offer prescription and over-the-counter medications at competitive prices compared to traditional pharmacies.
The North America market dominated the Global Motion Sickness Treatment Market by Region in 2022; thereby, achieving a market value of $179.4 Million by 2029. The Asia Pacific market is poised to grow at a CAGR of 3.9% during (2023 - 2029). Additionally, The Europe market would experience a CAGR of 3% during (2023 - 2029).
Full Report: https://www.kbvresearch.com/motion-sickness-treatment-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country-wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Viatris, Inc., Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals, Inc., Baxter International, Inc., Novartis AG, Abbott Laboratories, Sun Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd., Prestige Consumer Healthcare, Inc., WellSpring Pharmaceutical Corporation (Avista Capital Partners).
By Drug Class
By Route of Administration
By Distribution Channel
By Geography
Companies Profiled
Unique Offerings 
